The relationship of obesity to the metabolic syndrome

International Journal of Clinical Practice, Supplement

Volumn , Issue 134, 2003, Pages 18-27

  Lebovitz, Harold E ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; CYTOKINE; FATTY ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; CARDIOVASCULAR RISK; COMORBIDITY; CONFERENCE PAPER; DISEASE ASSOCIATION; HORMONE ACTION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

ADIPONECTIN; ADIPOSE TISSUE; ANTILIPEMIC AGENTS; BLOOD PROTEINS; BODY CONSTITUTION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; METABOLIC SYNDROME X; OBESITY; PROTEINS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0037990061     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Barrett-Connor EL. Obesity, atherosclerosis, and coronary artery disease. Ann Intern Med 1985; 103: 1010-1019.
2. Lapidus L, Bengtsson C, Larsson B et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow-up of participants in the population study of women in Gothenburg, Sweden. BMJ 1984; 289: 1257-1261.
3. Larsson B, Svardsudd K, Welin L et al. Abdominal adipose distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ 1984; 288: 1401-1404.
4. Boyko EJ, Leonetti DL, Fujimoto WY et al. Visceral adiposity and risk of type 2 diabetes. Diabetes Care 2000; 23: 465-471.
5. Chaiken RL, Banerji MA, Huey H et al. Do blacks with NIDDM have an insulin resistance syndrome? Diabetes 1993; 42: 444-449.
6. Banerji MA, Lebowitz J, Chaiken RL et al. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 1997; 273E: 425-432.
7. Bosello O, Zamboni M. Visceral obesity and the metabolic syndrome. Obes Rev 2000; 1: 47-56.
8. Banerji MA, Buckley MC, Chaiken RL et al. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obesity 1995; 19: 846-850.
9. Sinha R, Dufour S, Petersen KF et al. Assessment of skeletal muscle triglyceride content by H1 nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central obesity. Diabetes 2002; 51: 1022-1027.
10. Montague CT, O'Rahilly S. The perils of portliness. Causes and consequences of visceral adiposity. Diabetes 2000; 49: 883-888.
11. Brochu M, Tchernof A, Dionne IJ et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab 2001; 86: 1020-1025.
12. Hellmer J, Marcus C, Sonnenfeld T et al. Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells. J Clin Endocrinol Metab 1992; 75: 15-20.
13. Arner P, Hellstrom L, Wahrenberg H et al. Betaadrenoceptor expression in human fat cells from different regions. J Clin Invest 1990; 86: 1595-1600.
14. Fried SK, Russell CD, Grauso NL et al. Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissue of obese women and men, J Clin Invest 1993; 92: 2191-2198.
15. Van Harmelen V, Dicker A, Ryden M et al. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous adipocytes. Diabetes 2002; 51: 2029-2036.
16. Zierath J, Livingston J, Thorne A et al. Regional differences in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and insulin signaling through the insulin receptor substrate-1 pathway. Diabetologia 1998; 41: 1343-1354.
17. Mittleman SD, Van Citters GW, Kirkman EL et al. Extreme insulin resistance of the central adipose depot in vivo. Diabetes 2002; 51: 755-761.
18. Vikman H-L, Savola J-M, Raasmaja A et al. α2Aadrenergic regulation of cyclic AMP accumulation and lipolysis in human omental and subcutaneous adipocytes. Int J Obes 1996; 20: 185-189.
19. Paulmyer-Lacroix O, Boullu S, Oliver C et al. Expression of the mRNA coding for 11-β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002; 87: 2701-2705.
20. Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170.
21. Gravholt CH, Dall R, Christiansen JS et al. Preferential stimulation of abdominal subcutaneous lipolysis after prednisolone exposure in humans. Obes Res 2002; 10: 774-781.
22. Joyner J, Hutley L, Cameron D. Intrinsic regional differences in androgen receptors and dihydrotestosterone metabolism in human preadipocytes. Horm Metab Res 2002; 34: 223-228.
23. Adams M, Montague CT, Prins JB et al. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-3153.
24. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001; 56: 265-294.
25. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001; 109(Suppl 2): S135-S148.
26. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481.
27. Katsuki A, Sumida Y, Murata K et al. Troglitazone reduces plasma levels of tumour necrosis factor-α in obese patients with type 2 diabetes. Diabetes Obes Metab 2000; 2: 189-191.
28. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
29. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999; 892: 146-154.
30. Steppen CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
31. Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
32. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3019-3022.
33. Flier JS, Mantzoros C. Syndromes of insulin resistance and mutant insulin. In: DeGroot LJ, Jameson JL (eds.) Endocrinology, 4th Edn. WB Saunders Co; Philadelphia, USA; 2001: 799-809.
34. Chao L, Marcus-Samuels B, Mason MM et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic effect of thiazolidinediones. J Clin Invest 2000; 106: 1221-1228.
35. Dresner A, Laurent D, Marcucci M et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103: 253-259.
36. Itani SI, Ruderman NB, Schmieder F et al. Lipidinduced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 2002; 51: 2005-2011.
37. Niesler CU, Prins JB, O'Rahilly S et al. Adipose depot-specific expression of cIAP2 in human preadipocytes and modulation of expression by serum factors and TNF-α. Int J Obes Relat Metab Disord 2001; 25: 1027-1033.
38. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factoralpha-induced inhibition of insulin signaling. J Clin Invest 1997; 100: 1863-1869.
39. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
40. Baldwin AS Jr. The transcription factor NFκB and human disease. J Clin Invest 2001; 107: 3-6.
41. Tak PP, Firestone GS. NFκB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11.
42. Kim JK, Kim Y-J, Fillmore JJ et al. Prevention of fat-induced insulin resistance by salicylates. J Clin Invest 2001; 108: 437-446.
43. Yuan M, Konstantopoulos N, Lee J et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 2001; 293: 1673-1677.
44. Hundal RS, Petersen KF, Mayerson AB et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-1326.
45. Hotta K, Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126-1133.
46. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor γ and metabolic disease. Ann Rev Biochem 2001; 70: 341-367.
47. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 1998; 78: 783-809.
48. Rangwala SM, Lazar MA. Transcriptional control of adipogenesis. Ann Rev Nutr 2000; 20: 535-559.
49. Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 2000; 106: 459-465.
50. Ristow M, Wieland D-M, Pfeiffer A et al. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339: 953-959.
51. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-2791.
52. Hirose H, Kawai T, Yamamoto Y et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002; 51: 314-317.
53. Okuno A, Tamemoto H, Tobe K et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese zucker rats. J Clin Invest 1998; 101: 1354-1361.
54. Ghanim H, Garg R, Aljada A et al. Suppression of nuclear factor-κB and stimulation of inhibitor κB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86: 1306-1312.
55. Yu JG, Javorschi S, Hevener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type 2 diabetic subjects. Diabetes 2002; 51: 2968-2974.
56. Yang W-S, Matsuzawa Y, Jeng C-Y et al. Synthetic peroxisome proliferator-activated receptorγ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-380.
57. Martin G, Duez H, Blanquart C et al. Statininduced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-1. J Clin Invest 2001; 107: 1423-1432.
58. Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res 2002; 51(2): 58-62.
59. Zelvyte I, Dominaitiene R, Crisby M et al. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002; 45(2): 147-154.